Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NVMDF

Novamind To Offer Psychedelic-Assisted Group Therapy

Novamind Inc. (OTCQB:NVMDF) has announced that it will offer a model of psychedelic-assisted group therapy. Under the name Groups by Novamind, the therapy model will offer psychedelic integration and in-person group psychedelic-assisted psychotherapy for four to ten individuals delivered as drop-in sessions or multi-week curricula. According to the company, the…

Benzinga · Mar 24, 2022

Novamind Stock Slightly Up On Grants Restricted Share Units

Novamind Inc. (OTCQB:NVMDF)(CSE:NM)(FSE:HN2) a mental health company specialized in psychedelic medicine, has granted an aggregate of 325,000 restricted share units effective March 11, 2022, to certain executives and employees of the company pursuant to its restricted share unit plan. The RSUs will vest in 25% intervals, every 6 months from…

Benzinga · Mar 11, 2022

Novamind To Conduct Phase II Psilocybin Trial For Major Depressive Disorder

Novamind Inc. (OTCQB:NVMDF) (CSE:NM)(FSE:HN2) will conduct a phase II clinical trial investigating psilocybin for major depressive disorder sponsored by the Usona Institute. The company completed first patient randomization at its Draper, Utah research site.

Benzinga · Mar 9, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Psyched: First Australian Psych Company On Nasdaq, Utah's Psychedelics Bill, LSD Vs. Psilocybin Study Unprecedented Results

On the legislative front of the psychedelics space, a new bill meant to study the therapeutic effects of psychedelic substances received full approval in both Utah chambers, standing out from among dozens of measures currently circulating in legislatures across several U.S. states. Psychedelic science also took an important step forward with the publication…

Benzinga · Mar 7, 2022

Novamind Posts Record High Revenue Of CA$2.45M, Up 32% QoQ

Psychedelics-focused mental health company Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE: HN2) reported its financial results for the three and six months ended December 31, 2021.

Benzinga · Mar 2, 2022

Novamind To Host Clinical Trial To Advance Ketamine Therapy For End-of-Life Patients

Mental health company specialized in psychedelic medicine Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE:HN2) has been selected by the Ketamine Research Foundation to host a phase II clinical trial investigating ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness.

Benzinga · Feb 3, 2022

Novamind Stock Dives On $3.95M Private Placement With Institutional Investor

Novamind Inc. (CSE: NM) (OTCQB: NVMDF) (FSE: HN2) announced Monday a CA$5 million ($3.95 million) private placement with an institutional investor.

Benzinga · Jan 24, 2022

Read news from The Economist, FT, and more,
with one subscription

People

Alec Baldwin

1,129 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Johns Hopkins University

American Depositary Shares

15 stories

Incannex

11 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.